Cargando…
The effect of evolocumab alone and in combination with atorvastatin on atherosclerosis progression and TLRs expression
Evolocumab, a PCSK-9 inhibitor, is known for its ability to reduce low-density lipoprotein cholesterol (LDL-C). This study aimed to investigate the effects of evolocumab, alone or in combination with atorvastatin, on the progression of atherosclerosis. Fifty male domestic rabbits were randomly assig...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Carol Davila University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375357/ https://www.ncbi.nlm.nih.gov/pubmed/37520489 http://dx.doi.org/10.25122/jml-2021-0210 |